biopharma

Irving’s McKesson Corp. Completes Sale of Canada-Based Businesses to Private Equity Firm

by | Jan 2, 2025

Irving-based McKesson Corp. has finalized the sale of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a mid-market Canadian private equity firm.

McKesson said the deal enables it to focus capital deployment and prioritize investments expanding its strategic oncology and biopharma growth platforms.

The deal, which was announced in September, closed on Dec....

MORE
North Texas’ McKesson Launches InspiroGene to Support Commercialization of Cell and Gene Therapies
by | Oct 1, 2024
McKesson said that with a scalable, flexible suite of services and an experienced leadership team, InspiroGene enables manufacturers, payers, and providers to navigate the complex CGT commercialization landscape—ensuring that "patients can access the life-changing treatments they need."
MORE
Collaboration Is the Key to North Texas’ Emergence as a Bio-Hub
"When it comes to the biotech industry, our region is leading the U.S. in key metrics of job growth and investment," write Kathleen Otto and George Goodno. One proof point? VC funding is flowing into DFW at a faster rate than any other area in the nation.

These North Texas life science leaders say the region's success is no coincidence. Here's how the shared ambition of key players and strategic collaboration has impact.
MORE
Dallas Biopharma ReCode Therapeutics Closes $80M Series B Round to Expand Drug Pipeline for Respiratory Diseases
by | Oct 21, 2021
The funding, which was co-led by Pfizer Ventures and EcoR1 Capital, will help drive ReCode's therapy programs for primary ciliary dyskinesia and cystic fibrosis into human clinical studies.
MORE

Is DFW Becoming a Hub for Manufacturing? JLL Says It’s Trending That Way

by | Oct 2, 2017
An increasing number of companies are eyeing North Texas as a location to establish their large-scale manufacturing operations.
MORE